

BIOMARIN PHARMACEUTICAL INC  
 Form 4  
 January 03, 2008

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Swidler Stuart J

2. Issuer Name and Ticker or Trading Symbol  
 BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 SVP, Clinical Affairs

(Last) (First) (Middle)  
 C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
 01/02/2008

NOVATO, CA 94949  
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code			4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	M		12,500	A	\$ 6.13	22,500	D	
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S		642	D	\$ 35.96	21,858	D	
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S		100	D	\$ 35.97	21,758	D	
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S		500	D	\$ 35.99	21,258	D	
	01/02/2008 <sup>(1)</sup>	01/02/2008	S		750	D	\$ 36	20,508	D	

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock								
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	400	D	\$ 36.0001	20,108	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	100	D	\$ 36.0025	20,008	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	8	D	\$ 36.0501	20,000	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	150	D	\$ 36.1	19,850	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	1,100	D	\$ 36.11	18,750	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	1,250	D	\$ 36.1401	17,500	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	1,250	D	\$ 36.1801	16,250	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	470	D	\$ 36.3	15,780	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	740	D	\$ 36.31	15,040	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	40	D	\$ 36.32	15,000	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	209	D	\$ 36.48	14,791	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	300	D	\$ 36.49	14,491	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	441	D	\$ 36.5	14,050	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	300	D	\$ 36.51	13,750	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	1,250	D	\$ 35.28	12,500	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	1,250	D	\$ 36.0301	11,250	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	750	D	\$ 36.31	10,500	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	200	D	\$ 36.35	10,300	D
Common Stock	01/02/2008 <sup>(1)</sup>	01/02/2008	S	300	D	\$ 36.38	10,000	D

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
Stock Option (right to buy)	\$ 6.13	01/02/2008 <sup>(1)</sup>	01/02/2008	M	12,500	07/07/2005 <sup>(2)</sup> 01/06/2015	Common Stock 12,500

**Reporting Owners**

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Swidler Stuart J C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949			SVP, Clinical Affairs	

**Signatures**

/s/ G. Eric Davis, 01/03/2008  
Attorney-in-Fact

\_\_Signature of Reporting Person Date

**Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a Rule 10b5-1 Trading Plan.  
 (2) Original option grant vested 6/48ths on 7/7/2005 and 1/48th on the 7th of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.